ARTICLE | Clinical News
Ongentys opicapone regulatory update
May 9, 2016 7:00 AM UTC
EMA’s CHMP recommended approval of Ongentys opicapone from Bial-Portela as an adjunctive therapy to levodopa/ dopa decarboxylase (DDC; AADC) inhibitors in adults with Parkinson’s disease (PD) and end-...